<DOC>
	<DOCNO>NCT00675701</DOCNO>
	<brief_summary>This Phase 1 , double-blind , randomize , repeat-dose , single -dite , 4-arm parallel group study define ECG effect lixivaptan use therapeutic supratherapeutic dose compare placebo moxifloxacin ( positive control healthy adult men woman .</brief_summary>
	<brief_title>A Study Define ECG Effects Lixivaptan Compared Placebo Moxifloxacin Healthy Adult Men Women : A Thorough ECG Study</brief_title>
	<detailed_description />
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>1 . Healthy male female , 18 45 year age , inclusive 2 . Body mass index ( BMI ; see 279HAPPENDIX B ) within 18 32 kg/m2 , inclusive 3 . Absence significant disease determine medical history , physical examination , laboratory evaluation , 12lead ECG , vital sign ( conduct Screening admission clinic ) 4 . Normal 12lead ECG clinically significant abnormality rate , rhythm , conduction ( i.e. , normal PR interval 0.120.2 sec , normal QRS duration 0.060.1 sec , QTc Bazett &lt; 440 m male &lt; 470 ms female ) 5 . Clinical laboratory evaluation ( include serum chemistry panel [ fast least 8 hour ] , CBC , UA ) within reference range test laboratory . Laboratory finding outside normal reference range may repeat ; The subject may enrol laboratory finding outside normal reference range deem clinically significant investigator 6 . Negative test select drug abuse ( 280HAPPENDIX A ) Screening Checkin 7 . Women must postmenopausal ( 12 month since last period , verify FSH estradiol measurement ) ; surgically sterile ( hysterectomy tubal ligation least 6 month prior enrollment ) ; use intrauterine device ( include hormoneimpregnated device ) , double barrier ( i.e . diaphragm plus spermicide ) nonhormonal contraceptive therapy duration study ; must negative serum pregnancy test Screening Checkin 8 . Able communicate effectively study personnel 9 . Be adequately informed nature risk study able comprehend sign Informed Consent Form ( ICF ) prior study related procedure . 1 . Known hypersensitivity allergy lixivaptan ( VPA985 ) , vasopressin antagonist , moxifloxacin , fluoroquinolones ; 2 . Women pregnant breast feed 3 . A first degree relative Long QT Syndrome family history unexplained sudden death 4 . Any history , disease condition ( medical surgical ) , opinion investigator , might compromise hematologic , cardiovascular , pulmonary , renal , gastrointestinal , hepatic , urological , neurological , psychiatric , central nervous system ; condition might interfere absorption , distribution , metabolism , excretion study drug , would place subject increase risk 5 . History unexplained syncope 6 . History stomach intestinal surgery resection would potentially alter absorption and/or excretion orally administer drug ( appendectomy , hernia repair , and/or cholecystectomy allow ) 7 . History presence abnormal ECG , Investigator 's opinion , clinically significant 8 . Screening systolic blood pressure &lt; 90 mmHg &gt; 140 mmHg , and/or diastolic blood pressure &gt; 90 mmHg 9 . Screening heart rate &gt; 90 beat per minute 10 . Positive screen hepatitis B ( HBsAg ) , hepatitis C ( antiHCV ) , HIV ( antiHIV ) 11 . Participation investigational study within 30 day prior Checkin 12 . Any history alcohol abuse , illicit drug use , significant mental illness , physical dependence opioid , history drug abuse addiction within 6 month prior Checkin 13 . A history difficulty donate blood 14 . Donation â‰¥ 500 mL blood blood product within 45 day prior enrollment 15 . Receipt blood product within 2 month prior Checkin 16 . Use medication 281HTable 3 within give timeframe prior Checkin :</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2008</verification_date>
	<keyword>To determine whether lixivaptan administration supratherapeutic therapeutic dos result prolongation QTc interval .</keyword>
</DOC>